Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Clinical Oncology

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1999.17.9.2752PMID 10561350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

  1998cited by this paper
• Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

  1998cited by this paper
• Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

  1998cited by this paper
• The role of interferon alfa in the treatment of metastatic melanoma.

  1997cited by this paper
• Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.

  1997cited by this paper
• Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.

  1997cited by this paper
• Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.

  1997cited by this paper
• Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

  1997cited by this paper
• Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.

  1997cited by this paper
• Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.

  1996cited by this paper
• Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

  1996cited by this paper
• Prognostic factors in 1,521 melanoma patients with distant metastases.

  1995cited by this paper
• Systemic treatments for advanced cutaneous melanoma.

  1995cited by this paper
• Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

  1994cited by this paper
• Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.

  1994cited by this paper
• Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.

  1994cited by this paper
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

  1994cited by this paper
• Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?

  1994cited by this paper
• Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

  1993cited by this paper
• Interferon‐α and interleukin‐2 in the treatment of metastatic melanoma. Comparison of two phase II trials

  1993cited by this paper
• Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.

  1993cited by this paper
• A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma

  1993cited by this paper
• Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

  1992cited by this paper
• Cutaneous melanoma: prognosis and treatment results worldwide.

  1992cited by this paper
• Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

  1992cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• Studies of interferons in the therapy of melanoma.

  1991cited by this paper
• Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

  1990cited by this paper
• Current therapy for malignant melanoma.

  1989cited by this paper
• A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

  1989cited by this paper
• Complete responses and long‐term survivals after systemic chemotherapy for patients with advanced malignant melanoma

  1989cited by this paper
• Current therapy for malignant melanoma.

  1989cited by this paper
• Recombinant Interferons in the Management of Advanced Malignant Melanoma Updated Review of Five Prospective Clinical Trials and Long‐Term Responders

  1988cited by this paper
• Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)

  1984cited by this paper
• Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.

  1984cited by this paper
• A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).

  1983cited by this paper

• Carmustine Wafers (Gliadel) in Brain Metastases: Revisiting an Old Concept With New Insights

  2025cites this paper
• Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas

  2023cites this paper
• Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: A clinical study.

  2017cites this paper
• Sequencing of New and Old Therapies for Metastatic Melanoma

  2016cites this paper
• Metastasectomy for stage IV melanoma.

  2015cites this paper
• Gliadel for brain metastasis

  2013cites this paper
• Management of toxicities associated with high-dose interleukin-2 and biochemotherapy

  2013cites this paper
• Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses

  2012cites this paper
• Cytokine therapy in melanoma

  2010cites this paper
• Treatment for metastatic malignant melanoma: old drugs and new strategies.

  2010cites this paper
• Melanoma: From Darkness to Promise

  2010cites this paper
• Secondary Lung Tumors

  2010cites this paper
• Management of mucosal melanomas of the head and neck: did we make any progress?

  2010cites this paper
• Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

  2009cites this paper
• Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

  2009cites this paper
• The footprints of cancer development: Cancer biomarkers.

  2009cites this paper
• Novel therapeutics for melanoma

  2009cites this paper
• Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

  2009cites this paper
• Treatment options for metastatic melanoma. A systematic review

  2009cites this paper
• A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence

  2009cites this paper
• Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

  2008cites this paper
• Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

  2008cites this paper
• Systemic Therapy for Unresectable Metastatic Melanoma: Impact of Biochemotherapy on Long-Term Survival

  2008cites this paper
• A rational surgical approach to the treatment of distant melanoma metastases.

  2008cites this paper
• Biochemotherapy in patients with advanced head and neck mucosal melanoma

  2008cites this paper
• Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.

  2008cites this paper
• Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review.

  2008influential citation
• Chemotherapy for metastatic melanoma

  2007cites this paper
• Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy

  2007cites this paper
• The role of estrogen receptor in melanoma

  2007cites this paper
• Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine

  2007cites this paper
• Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control

  2007cites this paper
• Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma

  2006cites this paper
• Estrogen receptor-alpha methylation predicts melanoma progression.

  2006cites this paper
• Evaluation of immunotherapy in the treatment of melanoma.

  2006cites this paper
• Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.

  2006cites this paper
• Management of metastatic melanoma 2005.

  2006cites this paper
• Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.

  2006cites this paper
• Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

  2006cites this paper
• Estrogen receptor-α methylation predicts melanoma progression

  2006cites this paper
• A Review of Evidence-Based Treatment of Stage IIB to Stage IV Melanoma

  2005cites this paper
• Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.

  2005cites this paper
• A Retrospective Study of Biochemotherapy for Metastatic Melanoma: The Importance of Dose Intensity

  2005cites this paper
• Cell cycle proteins in laryngeal cancer: role in proliferation and prognosis.

  2005cites this paper
• Current Treatment Paradigms for the Management of Patients with Brain Metastases

  2005cites this paper
• Metastatic melanoma

  2005cites this paper
• Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.

  2005cites this paper
• Cyclosporine A, Alpha-Interferon and Interleukin-2 Following Chemotherapy with BCNU, DTIC, Cisplatin, and Tamoxifen: A Phase II Study in Advanced Melanoma

  2005cites this paper
• An era of rapid advancement: diagnosis and treatment of metastatic brain cancer.

  2005cites this paper
• Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.

  2005cites this paper
• Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy.

  2005cites this paper
• A Phase II Study of Biochemotherapy for Advanced Melanoma Incorporating Temozolomide, Decrescendo Interleukin-2 and GM-CSF

  2005cites this paper
• Is Biochemotherapy the Future

  2005cites this paper
• Case 3. Positron emission tomography-computed tomography diagnosis of metastatic melanoma with intussusception.

  2004cites this paper
• Management of metastatic cutaneous melanoma.

  2004cites this paper
• Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

  2004cites this paper
• Uncommon Presentations of Cancer Patients CASE 3. Positron Emission Tomography-Computed Tomgraphy Diagnosis of Metastatic Melanoma With Intussusception

  2004cites this paper
• Microsatellite Alterations as Diagnostic and Prognostic Molecular Markers in Patients With Cancer

  2004cites this paper
• Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate

  2004cites this paper
• Authors' Disclosures of Potential Conflicts of Interest Theauthorsindicatednopotentialconflictsofinterest.

  2004cites this paper
• Advances in Brief Allelic Imbalance on 12 q 22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome

  2004cites this paper
• Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome

  2004cites this paper
• Pancreaticoduodenectomy for pancreatic metastatic melanoma.

  2004cites this paper
• Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.

  2003cites this paper
• Low‐dose continuous chemotherapy for metastatic melanoma: a phase II trial

  2003cites this paper
• Tratamiento del melanoma metastásico

  2003cites this paper
• Metastatic malignant melanoma.

  2003cites this paper
• Biochemotherapy for Metastatic Melanoma with Limited Central Nervous System Involvement

  2003cites this paper
• Bioquimioterapia ambulatoria con cisplatino, dacarbacina, interleucina-2 e interferón-alfa en pacientes con melanoma avanzado. Estudio multicéntrico en 44 pacientes

  2003cites this paper
• Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine

  2003cites this paper
• Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

  2003influential citation
• Humoral I mmune R esponse t o a T herapeutic P olyvalent C ancer Vaccine A fter C omplete R esection o f T hick P rimary M elanoma and S entinel L ymphadenectomy

  2003cites this paper
• Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

  2003cites this paper
• Melanoma--new developments in diagnosis and therapy.

  2003cites this paper
• Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.

  2003cites this paper
• Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.

  2002cites this paper
• Metastatic melanoma: chemotherapy to biochemotherapy.

  2002cites this paper
• Granulocyte macrophage colony-stimulating factor: current practice and novel approaches.

  2002cites this paper
• Metastatic melanoma: chemotherapy.

  2002cites this paper
• Biochemotherapy for advanced melanoma.

  2002cites this paper
• Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.

  2002cites this paper
• L-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour ef®cacy of biochemotherapy in mice bearing B16 melanoma liver metastases

  2002cites this paper
• Clinical results using biochemotherapy as a standard of care in advanced melanoma

  2002cites this paper
• The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective.

  2002cites this paper
• Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.

  2002cites this paper
• l-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases

  2002cites this paper
• Biochemotherapy for melanoma.

  2002cites this paper
• Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.

  2001cites this paper
• Does Complete Resection of Melanoma Metastatic to Solid Intra-Abdominal Organs Improve Survival?

  2001cites this paper
• Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients.

  2001cites this paper
• High‐dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin‐2 in patients with metastatic melanoma

  2001influential citation
• Systemic chemotherapy.

  2000cites this paper
• Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.

  2000cites this paper
• Interleukin-2 in cancer

  2000cites this paper
• Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients

  2000cites this paper
• Biochemotherapy for melanoma

  2000cites this paper
• Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy.

  1999cites this paper